Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

Telix has paid an upfront cost of $230m to acquire 31 licenced radiopharmacies from RLS located across the US.

Iterum Therapeutics faces a mixed reception for its therapy for uncomplicated urinary tract infections (UTIs) as experts ...

The EMA CHMP has recommended granting approval for AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis ...

Takeda has secured the Japanese MHLW approval for its FRUZAQLA to treat unresectable advanced or recurrent colorectal cancer ...

The EC has granted marketing authorisation to LEO Pharma’s Anzupgo cream for treating adults with moderate to severe chronic ...

UCB has received US FDA approval for BIMZELX (bimekizumab-bkzx) to treat adults with three inflammatory conditions.

Discover how Memorial Sloan Kettering's new patent for innovative compounds could revolutionize treatments for Chagas disease, malaria, and sleeping sickness.

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

Discover Bicycle Therapeutics' groundbreaking patent for CD137-targeting polypeptides, offering innovative treatments for cancer and inflammation through peptide ligands.

Discover Ligand Pharmaceuticals' groundbreaking patent for fully human monoclonal antibodies targeting 4-1BB, designed to enhance cancer treatment through immune modulation.

Discover Protagonist Therapeutics' groundbreaking patent for CKRD peptides, designed to treat immune disorders and reduce inflammation in conditions like rheumatoid arthritis.